ROSEN, A GLOBALLY RESPECTED LAW FIRM , Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

Group 1 - The Rosen Law Firm is reminding purchasers of Regeneron Pharmaceuticals, Inc. securities from November 2, 2023, to October 30, 2024, about the March 10, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Regeneron securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that Regeneron made false and misleading statements regarding its pricing practices for Eylea, including undisclosed credit card fee payments to distributors that affected pricing [5] - It is claimed that these undisclosed payments led to a competitive advantage for Regeneron and resulted in inflated reported sales figures for Eylea [5] - The lawsuit also asserts that Regeneron's failure to report these payments as price concessions violated the False Claims Act, misleading investors about the company's business and prospects [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]